Study Title

FAPi Radioligand Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Dosimetry of [Lu-177]-PNT6555; A Dose Escalation Study for Treatment of Patients With Select Solid Tumors (FRONTIER)

Study Details

Description:

This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.

Sponsor:

Point Biopharma

Government Study Link:

NCT05432193 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States

Memorial Sloan Kettering Cancer Center